References
Rosso G, Rigardetto S, Bogetto F, Maina G. A randomized, single-blind, comparison of duloxetine with bupropion in the treatment of SSRI-resistant major depression. J Affect Disorders. 2012;136:172–6.
Hunziker ME, Suehs BT, Bettinger TL, Crismon ML. Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther. 2005;27:1126–43.
Zhang L, Chappell J, Gonzales CR, Small D, Knadler MP, Callaghan JT, et al. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study. J Cardiovasc Pharm. 2007;49:146–53.
Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2010;55:934–47.
Isbister GK, Balit CR. Bupropion overdose: QTc prolongation and its clinical significance. Ann Pharmacother. 2003;37:999–1002.
Conflict of interest
The authors have no personal affiliations, financial relationship, or any commercial interest to disclose relative to this article. The submitted report or any essential part of it is not published or simultaneously submitted to other publications prior to its appearance in this journal.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Štuhec, M. Duloxetine-induced life-threatening long QT syndrome. Wien Klin Wochenschr 125, 165–166 (2013). https://doi.org/10.1007/s00508-013-0330-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00508-013-0330-6